Maravai reports 28% mRNA revenue growth in third-quarter update
Company / institutional announcement · Maravai LifeSciences
Source published: · Event / reporting date: 2026-11-04
Site published: 2026-11-07 · Updated: 2026-11-07
This source is linked automatically. Choose a question to get started.
What changed
Maravai reported third-quarter 2026 revenue of $45.9 million, up 10.1% year over year, with a $24.0 million net loss and $5.8 million in adjusted EBITDA, a non-GAAP measure. The company said mRNA product revenue grew 28% and four discovery-stage mRNA customers moved to clinical-stage GMP. These figures describe company performance, not total RNA-market growth.
Why it may matter
Analysis: Customer progression may indicate demand for development-to-GMP support, although one supplier's revenue mix cannot establish industry-wide manufacturing trends.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Edited by the Biotech Assistant content team and reviewed by an authorized publisher. Editorial standards and corrections